The Anti-Malarial Drugs Market is estimated to be valued at US$ 989.7 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Anti-malarial drugs are used for prevention and treatment of malaria. The commonly used anti-malarial drugs include chloroquine, mefloquine, hydroxychloroquine, quinine, and artemisinin combination therapies (ACTs). Malaria is one of the major public health problems globally, especially in tropical and subtropical regions. According to WHO, around 228 million cases of malaria were reported globally in 2018.
One of the major drivers for growth of the anti-malarial drugs market is the increasing resistance of malaria parasites to existing drugs. For instance, malaria parasites in Southeast Asia have shown resistance to artemisinin-based combination therapies (ACTs) which were once the most effective treatments. This has reduced the effectiveness of existing anti-malarial drugs forcing pharmaceutical companies and research institutions to develop new drugs. Additionally, increasing investment by governments and non-profit organizations in malaria elimination programs is also expected to boost the demand for anti-malarial drugs for prevention and treatment over the forecast period.
The global anti-malarial drugs market is segmented by drug class into quinine, chloroquine, mefloquine, proguanil, pyrimethamine, atovaquone, halofantrine, doxycycline, and others. The quinine segment dominates the market and accounts for over 30% share of the global market. This is because quinine is recommended as the first-line treatment for uncomplicated P. falciparum malaria by WHO.
Political: Governments across malaria-endemic regions are working on various initiatives and awareness programs to curb the disease. This is promoting adoption of anti-malarial drugs.
Economic: As per WHO, malaria significantly impacts economic growth in endemic countries by reducing labor supply and capital formation. Treating malaria supports economic development.
Social: Non-government organizations are involved in social awareness programs about malaria prevention and treatment measures. This is increasing acceptability of anti-malarial drugs.
Technological: Rapid diagnostic tests have improved accuracy in identifying malaria parasites. This facilitates appropriate administration of anti-malarial drugs.
The global anti-malarial drugs market is expected to witness high growth, exhibiting CAGR of 4.5% over the forecast period, due to increasing investment by pharmaceutical companies in developing novel anti-malarial drugs.
The Asia Pacific region dominates the global market with over 40% share. This is attributed to high malaria prevalence in countries like India and Indonesia. Supportive government initiatives and low manufacturing costs attract pharmaceutical investments in the region.
Key players operating in the anti-malarial drugs market include Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd. Players are focused on new drug approvals and manufacturing partnerships to consolidate market position.